VTRS Overview

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.

Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Viatris Inc revenue for the last quarter amounts to 4.00B USD, increased 0.23 % YoY.

Viatris Inc. EPS for the last quarter amounts to -0.11 USD, decreased -237.50 % YoY.

Viatris Inc (VTRS) has 32000 emplpoyees as of January 30 2026.

Today VTRS has the market capitalization of 15.00B USD.